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Tailoring treatment in potentially resectable pancreatic cancer
Today’s oncological advances do help patients with borderline resectable pancreatic cancer. Nonetheless, some of the
aggressive chemoradiation neoadjuvant regimens are toxic mitigating the limited life extension they provide. We are
unable to explain to that occasional patient and family how or why they have been blessed with a complete response
to treatment, and will likely live on. We need an actionable biomarker that can accurately predict disease progression,
stability or regression. So far, all we really have is Ca 19-9. It is probably only best at alerting to disease recurrence
rather than response to therapy. Aldakkak et al focused on pre-treatment CA19-9 levels in non-jaundiced pancreatic
cancer patients being considered for resectional surgery. Normalisation of CA19-9 levels was most marked in those
with low levels (36–200 U/ml) although this occurred in only half of the treated patients. Responses were much
poorer, the higher the preoperative levels. Seventy-one per cent of patients completed intended therapy including
tumour resection but the pretreatment levels were not predictive of survival. The authors suggest that post-treatment
normalisation was highly prognostic. The disappointment remains that a significant proportion of patients never come
to resection. There is frustration that for those patients whose CA19-9 identifies a poor outlook, and we have little else
to offer as effective treatment. CA 19-9 remains our only biomarker for pancreatic cancer, and its role likely remains
limited to disease progression. We believe this will change in new years ahead, and will report to our readership
clinically significant discoveries in biomarkers of pancreatic cancer.
Mark Callery
Surgery outperforms radiofrequency ablation as a treatment for small
hepatocellular carcinomas
Radiofrequency ablation (RFA) has emerged as a useful option for treating some patients with hepatocellular carci-
noma (HCC) but exactly where it fits in the management options is less clear. The best results from RFA are predicted
in patients with small tumours <3 cm in diameter.
Miura and colleagues from the Medical College of Wisconsin have undertaken an analysis of outcomes from almost
3000 patients who either underwent surgical resection (SR) or RFA for HCC 3 cm or smaller in diameter. As might
be expected from a non-randomised retrospective study there were some differences between the groups in terms of
proportion with cirrhosis and alphafetoprotein levels (both higher in RFA group). In the overall analysis the resection
group had a better unadjusted survival at 5 years of 67% compared with 55% for RFA. The group then applied
propensity scoring to attempt to overcome the selection bias between the two groups and after matching the survival
benefit of surgical resection was maintained at 54% overall 5 year survival compared with 37% for the RFA group.
Other factors associated with adverse outcome for RFA included older patients and those with cirrhosis. A further
analysis excluded patients who underwent ablation using non thermal techniques but again the disadvantage in
survival from RFA remained evident.
The authors conclude that RFA is inferior to surgical resection and that treatment strategies should emphasize a
surgical resection first approach reserving RFA for patients with HCC in whom surgery is either unsafe or not desired
by the patient.
Stephen J. Wigmore
The big picture of minimally invasive liver resection
In this issue of HPB, He et al analyse two North American population databases (NSQIP and NIS) over the last dec-
ade to determine the trends in minimally invasive (MIS) liver resection. What struck this reader was the relatively low
frequency with which MIS liver surgery was being performed and how discrepant the figures appear from single insti-
tutional series. In the NIS database, the percentage of liver resections performed by MIS approach increased to just
6% in 2012, while for NSQIP, the proportion dropped from 7% in 2005 to 4% in 2012. However, it is important to
acknowledge the actual mean annual volume of MIS resections increased over time but the total number of resections
performed annually increased at a greater rate. Presumably, this corresponds to expanding indications for hepatic
surgery during this time period. Perhaps reassuringly, the rate of resection in both the open and MIS groups for
non-neoplastic disease was similar, suggesting that the indication for resection in this subgroup has not altered with
the advent of MIS liver resection.
In terms of outcomes, it is hard to decipher much from the data. It is clear that appropriate patient selection
occurred with smaller resections featuring more prominently in the MIS group in the NSQIP database. The effect of
MIS liver resection on morbidity and mortality remains unclear with only one database showing a reduction in favour
of the MIS group. This effect did not appear to remain significant after multivariate analysis. The median hospital stay
between the two surgical techniques was remarkably similar with the larger NIS database reporting a statistically
significant reduction of one day, yet these figures would not appear clinically significant in the age of ERAS pathways.
Therefore, the overall benefit of a MIS approach remains unclear. No long term quality of life, survival or economic
analyses are provided. This study provides a real world snapshot of the evolution of MIS liver surgery over the last
decade. It is important since it provides a benchmark at a population level rather than figures generated from an
individual centre of excellence.
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